GENY Spółka Akcyjna (KRS 0000997611, NIP 7812041843) is a Polish company, headquartered in Poznań, Wielkopolskie voivodeship. GENY operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since October 20, 2022. GENY's most recently reported net revenue was 0 PLN for 2023. GENY's operations are currently suspended.
The company is currently suspended
Suspended since February 1, 2026
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - GENY
Identity
- Name
- GENY Spółka Akcyjna
- Legal form
- Joint-Stock Company (S.A.)
- Founded
- October 20, 2022
- Registry status as of
- February 11, 2026
- Latest entry
- February 10, 2026
- Founding act
- 31.05.2022 R., KANCELARIA NOTARIALNA NOTARIUSZA JĘDRZEJA BASIŃSKIEGO, UL. JACKOWSKIEGO 13/1, 60-508 POZNAŃ, REPERTORIUM …
Articles of association history (1)
- May 31, 2022: 31.05.2022 R., KANCELARIA NOTARIALNA NOTARIUSZA JĘDRZEJA BASIŃSKIEGO, UL. JACKOWSKIEGO 13/1, 60-508 POZNAŃ, REPERTORIUM A NR 3753/2022
Activities
Other activities
Address and contact
- Address
- UL. JANA HENRYKA DĄBROWSKIEGO, 77A, 60-529, POZNAŃ, POLSKA
- Voivodeship
- WIELKOPOLSKIE
- District
- POZNAŃ
- CZ@BLUMERANG.PL
- Website
- HTTP://WWW.GENLIFE.PL/
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 52.4079, 16.9335approx.
Risk and payment profile - GENY
Credibility rating
5 / 100
Very poor credibility
Insolvency risk
suspended
Significant formal threat
Closure risk
80
/ 100
Extremely high risk
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/4 yrs
Board changes
1
1/4 yrs
PKD changes
0
0/4 yrs
Name changes
0
0/4 yrs
Data from 4 years of registry activity.
Credibility history
Payment reliability score from 2022–2023
Current: S (5/100)
Trend: stable (0.0 pts/year)
Spółka jest obecnie zawieszona – działalność operacyjna wstrzymana, wskaźnik wiarygodności odzwierciedla stan przed zawieszeniem.
Trade credit limit history
Standard limit from 2022–2023
Current: 10.9 K PLN
Safe: 1.9 K PLN
Operational status - GENY
Founded
October 20, 2022
3 years in operation
Legal form
Joint-Stock Company (S.A.)
Registry: RejP
Headquarters
POZNAŃ
WIELKOPOLSKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
600.0 K PLN
Shareholders
historical only
Board
1 person
Sup. board: 3
Filed years
2 years
2022–2023 · profitable: 0/2
Registry entries
13
latest: February 10, 2026
Risk signals
Revenue
0 PLN
2023
Net profit
-24.5 K PLN
2023
Assets
572.1 K PLN
2023
Equity
555.4 K PLN
2023
EBITDA
-24.5 K PLN
2023
Valuation
0 PLN
suspended
Board and connected people - GENY
People holding roles at GENY according to the Polish National Court Register. Follow a name for that person's full profile and their other companies.
- Cezary Piotr ZiarkowskiBoard member
- Łukasz ParafianowiczBoard member
- Andrzej WiczewskiSupervisory board member
- Jacek Marek WojciechowiczSupervisory board member
- Marcin MuraszkoSupervisory board member
Directories and rankings for this location
Public procurement
Trademarks
Reviews
Rate business credibility - GENY.
No ratings
Related articles
Explainer
Mabion in 2026: Polish monoclonal-antibody maker, mWIG40 issuer from Konstantynów Łódzki, Novavax COVID-19 antigen contract
Mabion S.A. (KRS 0000340462), headquartered at ul. Gen. Mariana Langiewicza 60 in Konstantynów Łódzki, is a Polish biotech specialising in monoclonal-antibody production (key project: MabionCD20, a rituximab biosimilar) and in CDMO (Contract Development and Manufacturing Organization) work. Its main international contract is manufacturing the COVID-19 vaccine antigen for Novavax. Founded in 2007 by Maciej Wieczorek and listed on the WSE since 2010, the company is an mWIG40 constituent, with a three-member management board and a five-member supervisory board.
Explainer
Ryvu Therapeutics in 2026: a Kraków oncology biotech, RVU120 in Phase II clinical trials, a six-member management board, an mWIG40 issuer after the Selvita spin-off
Ryvu Therapeutics S.A. (KRS 0000367359), headquartered at ul. Leona Henryka Sternbacha 2 in Kraków, is a Polish oncology biotech developing anti-cancer small-molecule drugs. It has operated as a stand-alone company since the 2019 spin-off from Selvita (which retained the R&D-services business). Flagship project: RVU120 – a CDK8/19 kinase inhibitor in Phase II trials across multiple oncological indications. Listed on the WSE since 2019 and an mWIG40 constituent, with a six-member management board and a seven-member supervisory board.